Found 150 clinical trials
ATRA and Carfilzomib in Plasma Cell Myeloma Patients (ATRA)
all hematologic malignancies. Over the past 30 years the global prevalence of multiple myeloma has risen to 126%, with 85% of diagnoses occurring in patients >55 years of age. In the past 15 years
- 0 views
- 25 Jun, 2025
The Norwegian Immunotherapy in Multiple Myeloma Study (NIMMS)
The goal of this observational study is to study the effectiveness and complications of novel immunotherapies used in the treatment of multiple myeloma in routine care in Norway. The aim is to
- 0 views
- 25 Jun, 2025
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients
- 0 views
- 03 Jul, 2025
- 16 locations
VitD3 Supplementation in Patients With Multiple Myeloma
The goal of this clinical trial is to evaluate post-transplant immune reconstitution and lymphocyte recovery as well as the 3-year progression-free survival of patients with multiple myeloma in
- 0 views
- 03 Jul, 2025
- 1 location
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
multiple myeloma that has gotten worse and is not responding to standard drugs that are used for treating multiple myeloma, including chimeric antigen receptor T-cell therapy.Participation in this research
- 0 views
- 03 Jul, 2025
- 1 location
MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
This trial is an adaptive platform trial. The structure of the protocol allows the trial to evolve over time. Multiple investigational arms will be included within the trial under a Master Protocol (MP). These investigational arms may be added as appendices at different times depending on whether they are trial-ready …
- 0 views
- 01 May, 2025
- 1 location
Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (SINE)
not respond to treatment. Drugs used in chemotherapy, such as selinexor and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from
- 0 views
- 06 May, 2025
- 1 location
MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
This trial is an adaptive platform trial. The structure of the protocol allows the trial to evolve over time. Multiple investigational arms will be included within the trial under a Master Protocol (MP). These investigational arms may be added as appendices at different times depending on whether they are trial-ready …
- 0 views
- 31 Jul, 2025
- 8 locations
Modeling and characterizing early ALK-dependent tumorigenesis
insights to guide strategies for early detection, intervention, disruption of cancer progression, and ultimately to cure patients with ALK+ lung cancer. Limited access to early-stage ALK+ patient samples has
- 0 views
- 10 Jan, 2025
- 1 location
Patient-centered, Optimal Integration of Survivorship and Palliative Care
confidence in their ability to manage cancer, and their understanding about what to expect Participants in the randomized controlled trial will receive either the new supportive care model, POISE, which
- 0 views
- 10 Jan, 2025
- 1 location